176 related articles for article (PubMed ID: 20213318)
21. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
Gatto S; Scappini B; Pham L; Onida F; Milella M; Ball G; Ricci C; Divoky V; Verstovsek S; Kantarjian HM; Keating MJ; Cortes-Franco JE; Beran M
Haematologica; 2003 Aug; 88(8):853-63. PubMed ID: 12935973
[TBL] [Abstract][Full Text] [Related]
22. TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells.
Uno K; Inukai T; Kayagaki N; Goi K; Sato H; Nemoto A; Takahashi K; Kagami K; Yamaguchi N; Yagita H; Okumura K; Koyama-Okazaki T; Suzuki T; Sugita K; Nakazawa S
Blood; 2003 May; 101(9):3658-67. PubMed ID: 12506034
[TBL] [Abstract][Full Text] [Related]
23. Aldose reductase inhibition enhances TRAIL-induced human colon cancer cell apoptosis through AKT/FOXO3a-dependent upregulation of death receptors.
Shoeb M; Ramana KV; Srivastava SK
Free Radic Biol Med; 2013 Oct; 63():280-90. PubMed ID: 23732517
[TBL] [Abstract][Full Text] [Related]
24. A small molecule Abl kinase inhibitor induces differentiation of Abelson virus-transformed pre-B cell lines.
Muljo SA; Schlissel MS
Nat Immunol; 2003 Jan; 4(1):31-7. PubMed ID: 12469118
[TBL] [Abstract][Full Text] [Related]
25. Active Akt and functional p53 modulate apoptosis in Abelson virus-transformed pre-B cells.
Gong L; Unnikrishnan I; Raghavan A; Parmar K; Rosenberg N
J Virol; 2004 Feb; 78(4):1636-44. PubMed ID: 14747529
[TBL] [Abstract][Full Text] [Related]
26. Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion.
Wei W; Huang H; Zhao S; Liu W; Liu CX; Chen L; Li JM; Wu YL; Yan H
Apoptosis; 2013 Sep; 18(9):1060-70. PubMed ID: 23613107
[TBL] [Abstract][Full Text] [Related]
27. FOXO3a induces differentiation of Bcr-Abl-transformed cells through transcriptional down-regulation of Id1.
Birkenkamp KU; Essafi A; van der Vos KE; da Costa M; Hui RC; Holstege F; Koenderman L; Lam EW; Coffer PJ
J Biol Chem; 2007 Jan; 282(4):2211-20. PubMed ID: 17132628
[TBL] [Abstract][Full Text] [Related]
28. The v-abl tyrosine kinase negatively regulates NF-kappa B/Rel factors and blocks kappa gene transcription in pre-B lymphocytes.
Klug CA; Gerety SJ; Shah PC; Chen YY; Rice NR; Rosenberg N; Singh H
Genes Dev; 1994 Mar; 8(6):678-87. PubMed ID: 7926758
[TBL] [Abstract][Full Text] [Related]
29. Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell line.
Gordon PM; Fisher DE
J Biol Chem; 2010 May; 285(19):14109-14. PubMed ID: 20231287
[TBL] [Abstract][Full Text] [Related]
30. FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism.
Fernández de Mattos S; Essafi A; Soeiro I; Pietersen AM; Birkenkamp KU; Edwards CS; Martino A; Nelson BH; Francis JM; Jones MC; Brosens JJ; Coffer PJ; Lam EW
Mol Cell Biol; 2004 Nov; 24(22):10058-71. PubMed ID: 15509806
[TBL] [Abstract][Full Text] [Related]
31. BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription.
Sheng Z; Ma L; Sun JE; Zhu LJ; Green MR
Blood; 2011 Sep; 118(10):2840-8. PubMed ID: 21715304
[TBL] [Abstract][Full Text] [Related]
32. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Dai Y; Rahmani M; Pei XY; Dent P; Grant S
Blood; 2004 Jul; 104(2):509-18. PubMed ID: 15039284
[TBL] [Abstract][Full Text] [Related]
33. The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-κB/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis.
Baritaki S; Militello L; Malaponte G; Spandidos DA; Salcedo M; Bonavida B
Int J Oncol; 2011 Jun; 38(6):1683-94. PubMed ID: 21455568
[TBL] [Abstract][Full Text] [Related]
34. NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants.
Lounnas N; Frelin C; Gonthier N; Colosetti P; Sirvent A; Cassuto JP; Berthier F; Sirvent N; Rousselot P; Dreano M; Peyron JF; Imbert V
Int J Cancer; 2009 Jul; 125(2):308-17. PubMed ID: 19378338
[TBL] [Abstract][Full Text] [Related]
35. BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.
De Carvalho DD; Binato R; Pereira WO; Leroy JM; Colassanti MD; Proto-Siqueira R; Bueno-Da-Silva AE; Zago MA; Zanichelli MA; Abdelhay E; Castro FA; Jacysyn JF; Amarante-Mendes GP
Oncogene; 2011 Jan; 30(2):223-33. PubMed ID: 20838376
[TBL] [Abstract][Full Text] [Related]
36. Doxorubicin induces atypical NF-κB activation through c-Abl kinase activity in breast cancer cells.
Esparza-López J; Medina-Franco H; Escobar-Arriaga E; León-Rodríguez E; Zentella-Dehesa A; Ibarra-Sánchez MJ
J Cancer Res Clin Oncol; 2013 Oct; 139(10):1625-35. PubMed ID: 23892407
[TBL] [Abstract][Full Text] [Related]
37. Temperature-sensitive transformation by an Abelson virus mutant encoding an altered SH2 domain.
Mainville CA; Parmar K; Unnikrishnan I; Gong L; Raffel GD; Rosenberg N
J Virol; 2001 Feb; 75(4):1816-23. PubMed ID: 11160680
[TBL] [Abstract][Full Text] [Related]
38. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.
Allen JE; Krigsfeld G; Mayes PA; Patel L; Dicker DT; Patel AS; Dolloff NG; Messaris E; Scata KA; Wang W; Zhou JY; Wu GS; El-Deiry WS
Sci Transl Med; 2013 Feb; 5(171):171ra17. PubMed ID: 23390247
[TBL] [Abstract][Full Text] [Related]
39. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Mitsiades CS; Mitsiades N; Poulaki V; Schlossman R; Akiyama M; Chauhan D; Hideshima T; Treon SP; Munshi NC; Richardson PG; Anderson KC
Oncogene; 2002 Aug; 21(37):5673-83. PubMed ID: 12173037
[TBL] [Abstract][Full Text] [Related]
40. NF-kappaB1 can inhibit v-Abl-induced lymphoid transformation by functioning as a negative regulator of cyclin D1 expression.
Nakamura Y; Grumont RJ; Gerondakis S
Mol Cell Biol; 2002 Aug; 22(15):5563-74. PubMed ID: 12101248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
